Ergometrine or carbetocin injections to reduce bleeding in surgery for uterine fibroids
Compares ergometrine and carbetocin injected into the uterus to reduce bleeding in fibroid surgery.
Key facts
- Who runs it
- Cairo University
- Where
- Egypt1 site in 1 countryChoose a country to see its sites
- Trial code
- Registry title
- Ergometrine Versus Carbetocin to Decrease Blood Loss in Myomectomy
- Status
- Recruiting
- People taking part
- 40 people, planned
- Started
- 18 Jan 2026
- Planned end
- 30 Aug 2026
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Methylergometrine (Intramyometrial Injection)
- Carbetocin (Intramyometrial Injection)
- Record updated
- 5 February 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for women with uterine fibroids that cause symptoms, who are planned to have the fibroids removed through an open abdominal operation. It compares two drugs injected into the womb muscle to reduce bleeding.
- Age
- 25 to 48 years
- Sex
- Women only
- Disease stage
- Fibroids inside the womb wall, FIGO types 3 to 6, seen on ultrasound or MRI. They cause symptoms such as abnormal bleeding, pelvic pain or pressure and need surgery. The largest fibroid is at most 20 cm (7.9 in). Body mass index (BMI) below 35 kg/m².
- Earlier treatment
- No earlier surgery on the womb. No hormone treatment in the 3 months before joining.
Main reasons for not taking part
- Fibroids of FIGO type 0, 1, 2, 7 or 8, or a past pelvic or abdominal infection
- High blood pressure, heart or lung disease, diabetes or other long-term hormone or metabolic disease, kidney or liver problems
- Allergy to methylergometrine or carbetocin
- Bleeding disorders, use of blood thinners or antiplatelet drugs, or hemoglobin below 10 g/dL
- BMI of 35 kg/m² or more, or the operation changed to removal of the womb
The registry criteria, word for word
Show all 23 criteriaShow less
Who can take part
- Female participants aged 25 to 48 years
- Body mass index (BMI) < 35 kg/m²
- Symptomatic uterine fibroids requiring surgical management (e.g., abnormal uterine bleeding, pelvic pain, or pressure symptoms)
- Intramyometrial uterine myomas classified as FIGO types 3 to 6, diagnosed by transvaginal ultrasonography or magnetic resonance imaging
- Maximum diameter of the largest myoma ≤ 20 cm
- Eligible for and scheduled to undergo abdominal myomectomy
- Able and willing to provide written informed consent
Who cannot take part
- History of prior uterine surgery
- Use of hormonal treatment within 3 months prior to enrollment
- Current use of antiplatelet or anticoagulant therapy
- History of pelvic inflammatory disease, peritonitis, or significant abdominal or pelvic infection
- Known drug allergy
- Hypertension
- Cardiac or pulmonary disease
- Chronic endocrine or metabolic disease (e.g., diabetes mellitus)
- Renal or hepatic impairment
- High risk of bleeding, including:
- Known bleeding disorders
- Preoperative anemia (hemoglobin < 10 g/dL)
- FIGO type 0, 1, 2, 7, or 8 myomas (intracavitary, submucosal, pedunculated subserosal, cervical, or adnexal)
- Contraindication to methylergometrine or carbetocin, including:
- BMI ≥ 35 kg/m²
- Intraoperative conversion from myomectomy to hysterectomy
The main criteria, as questions
These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Are you between 25 and 48 years old?
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The goal of this randomized clinical trial is to determine whether intramyometrial ergometrine injection or intramyometrial carbetocin injection is more effective in reducing blood loss during and after abdominal myomectomy in women undergoing surgery for symptomatic uterine fibroids.
Read full original descriptionShow less
The main questions it aims to answer are:
Does intramyometrial ergometrine reduce intraoperative and postoperative blood loss during abdominal myomectomy?
Does intramyometrial carbetocin reduce intraoperative and postoperative blood loss during abdominal myomectomy?
Is there a difference between the two drugs in the need for blood transfusion and postoperative hemoglobin drop?
Researchers will compare intramyometrial ergometrine injection with intramyometrial carbetocin injection to see which intervention is more effective in controlling surgical bleeding and improving surgical outcomes.
Participants will:
Undergo abdominal myomectomy for uterine fibroids
Receive either intramyometrial ergometrine or intramyometrial carbetocin during surgery
Be monitored for intraoperative blood loss, postoperative blood loss, hemoglobin changes, and need for blood transfusion
The 2 groups in the trial
- Intramyometrial Ergometrine InjectionExisting treatment, for comparison
Participants receive intramyometrial injection of methylergometrine maleate diluted in saline and administered circumferentially around the myoma before uterine incision during abdominal myomectomy.
Treatment: Methylergometrine (Intramyometrial Injection)
- Intramyometrial Carbetocin InjectionTreatment being tested
Participants receive intramyometrial injection of carbetocin diluted in saline and administered circumferentially around the myoma before uterine incision during abdominal myomectomy.
Treatment: Carbetocin (Intramyometrial Injection)
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Intramyometrial Ergometrine Injection Versus Intramyometrial Carbetocin Injection to Decrease Blood Loss During and After Abdominal Myomectomy: A Randomized Clinical Trial
- Plain-language title
- Ergometrine or carbetocin injections to reduce bleeding in surgery for uterine fibroidsGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 15 November 2026.
- Criteria questions
- Built from NCT07390864, who can take part
- Record updated
- 5 February 2026